Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory faolure, but not the organ injury/dysfunction, caosed by endotoxin

Shock

Volumn 9, Issue 5, 1998, Pages 329-335

  Wray, Gillian M ^a   Millar, Colin G ^a   Hinds, Charles J ^a   Thiemermann, Christoph ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDINE; BENZYLAMINE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; LYSINE; N (3 (AMINOMETHYL)BENZYL)ACETAMIDINE; N(6) (1 IMINOETHYL)LYSINE; N(6)-(1-IMINOETHYL)LYSINE; N-(3-(AMINOMETHYL)BENZYL)ACETAMIDINE; NITRATE; NITRIC OXIDE SYNTHASE; NITRITE; NOS2 PROTEIN, RAT;

ANIMAL; ARTICLE; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; ESCHERICHIA COLI; HEMODYNAMICS; INJURY; KIDNEY; LIVER; MALE; MULTIPLE ORGAN FAILURE; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SEPTIC SHOCK;

AMIDINES; ANIMALS; BENZYLAMINES; ENZYME INHIBITORS; ESCHERICHIA COLI; HEMODYNAMIC PROCESSES; KIDNEY; LIPOPOLYSACCHARIDES; LIVER; LYSINE; MALE; MULTIPLE ORGAN FAILURE; NITRATES; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; RATS; SHOCK, SEPTIC;

EID: 0032059870     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199805000-00003     Document Type: Article

References (41)

1. Thiemermann C, Vane JR: Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharide in the rat. Eur J Pharmacol 182:591-595, 1990.
2. Julou-Schaeffer G, Gray GA, Fleming I, Schott C, Parratt JR, Stoclet JC: Loss of vascular responsiveness induced by endotoxin involves the L-arginine pathway. Am J Physiol 259:H1038-H1043, 1990.
3. Rees DD, Cellek S, Palmer RMJ, Moncada S: Dexamethasone prevents the induction of nitric oxide synthase and the associated effects on the vascular tone: an insight into endotoxic shock. Biochem Biophys Res Commun 173:541-547, 1990.
4. G-monomethyl-L-arginine, an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 172:1132-1138, 1990.
5. Thiemermann C: The role of L-arginine:nitric oxide pathway in circulatory shock. Adv Pharmacol 28:45-79, 1994.
6. G-monomethyl-L-arginine, an inhibitor of the nitric oxide synthetase. Intensive Care Med 19:227-231, 1993.
7. Lorente JA, Landin L, De Pablo R, Renes E, Liste D: L-Arginine pathway in the sepsis syndrome. Crit Care Med 21:1287-1295, 1993.
8. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P: Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 28:34-39, 1994.
9. Thiemermann C: The use of selective inhibitors of inducible nitric oxide synthase in septic shock Sepsis 1998. In press.
10. Corbett JA, Tilton RG, Chang K, et al: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41:552-558, 1992.
11. Ruetten H, Southan GJ, Abate A, Thiemermann C: Attenuation of the multiple organ dysfunction caused by endotoxin by 1-amino-2-hydroxyguanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 118:261-270, 1996.
12. Garvey EP, Oplinger JA, Tanoury GJ, et al: Potent and selective inhibition of human nitric oxide synthases: Inhibition by non-amino acid isothioureas. J Biol Chem 269:26669-26676, 1994.
13. Southan G, Szabo C, Thiemermann C: Isothioureas: Potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol 114:510-516, 1995.
14. Conner JR, Manning PT, Settle SL, et al: Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 273:15-23, 1995.
15. Southan GJ, Szabo C: Selective pharmacological inhibition of distinct nitric oxide synthase isoforms: Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 51:383-394, 1996.
16. MacMicking JD, Nathan C, Hom G, et al: Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 82:641-650, 1995.
17. Wei X, Charles IG, Smith A: Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375:408-411, 1995.
18. Wu CC, Chen SJ, Szabo C, Thiemermann C, Vane JR: Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol 114:1666-1672, 1995.
19. Thiemermann C, Ruetten H, Wu CC, Vane JR: The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 116: 2845-2851, 1995.
20. Laubach VE, Sheseley EG, Smithies O, Sherman PA: Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci USA 92:10668-10692, 1995.
21. Misko TP, Moore WM, Kasten TP, et al: Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 233:119-125, 1993.
22. Griffith MJ, Messent M, MacAllister RJ, Evans TW: Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 110: 963-968, 1993.
23. G-nitro-L-arginine and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 199:147-154, 1994.
24. Bieganski T, Kusche J, Lorenz W, Hesterberg R, Stahlknecht CD, Feussner KD: Distribution and properties of human diamine oxidase and its relevance for the histamine catabolism. Biochem Biophys Acta 756:196-203, 1983.
25. Seiler N, Bolkenius FN, Knodgen B: The influence of catabolic reactions on polyamine excretion. Biochem J 225:219-226, 1985.
26. Ou P, Wolff SP: Aminoguanidine: A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol 46:1139-1144, 1993.
27. Picard S, Parthasarathy S, Fruebis J, Witzum JL: Aminoguanidine inhibits oxidative modification of low density lipoprotein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 89:6876-6880, 1992.
28. Ruetten H, Thiemermann C: Prevention of the expression of inducible nitric oxide synthase by aminoguanidine or aminoethyl-isothiourea in macrophages and in the rat. Biochem Biophys Res Commun 225:525-530, 1996.
29. Southan GJ, Szabo C, O'Conner MP, Salzman AC, Thiemermann C: Amidines are potent inhibitors of nitric oxide synthases: Preferential inhibition of the inducible isoform. Eur J Pharmacol 291:311-318, 1995.
30. Garvey EP, Oplinger JA, Furfine ES, et al: 1400W is a slow, tight binding, and highly selective inhibitor of inducible nitric oxide synthase in vitro and in vivo. J Biol Chem 272:4959-4963, 1997.
31. Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, Currie MG: L-N6-(1-iminoethyl)lysine: A selective inhibitor of inducible nitric oxide synthase. J Med Chem 37:3886-3888, 1994.
32. Salvemini D, Wang ZQ, Wyatts PS, et al: Nitric oxide: A key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br J Pharmacol 118:829-838, 1996.
33. Ridger VC, Pettipher ER, Bryant CE, Brain SD: Effect of inducible nitric oxide synthase inhibitors aminoguanidine and L-N6-(1-iminoethyl)lysine on zymosan-induced plasma extravasation in rat skin. J Immunol 159:383-390, 1997.
34. Moralez-Ruiz M, Jiminez W, Ros J, et al: Nitric oxide production in peritoneal macrophages of cirrhotic rats: A host response against bacterial peritonitis. Gastroenterology 112:2056-2064, 1997.
35. Faraci WS, Nagel AA, Verdies KA, et al: 2-amino-4-pyrimidine is a potent inhibitor of inducible NO synthase activity in vitro and in vivo. Br J Pharmacol 119:1101-1108, 1996.
36. Baue AE: The multiple organ or system failure syndrome. In Schlag G, Redl H, (eds): Pathophysiology of Shock, Sepsis and Organ Failure. Berlin: Springer Verlag, 1993, pp 1004-1018.
37. Schmidt HHHW, Warner TD, Nakane M, Forstermann U, Murad F: Regulation and subcellular location of nitric oxide synthases in RAW264.7 macrophages. J Pharmacol Exp Ther 41:615-621, 1992.
38. Green LC, Ruiz de Luzuriaga K, Wagner DA: Nitrate biosynthesis in man. Proc Natl Acad Sci USA 78:7764-7768, 1981.
39. Millar C, Thiemermann C: Intrarenal hemodynamics and renal dysfunction in endotoxemia: Effects of nitric oxide synthase inhibition. Br J Pharmacol 121:1824-1830, 1997.
40. Szabo C, Mitchell J, Theimermann C, Vane JR: Nitric oxide mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxic shock. Br J Pharmacol 108:786-792, 1993.
41. Kilbourn RG, Szabo C, Traber D: Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: Lessons learned from experimental and clinical studies. Shock 7:235-246, 1997.